These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 11192865)
21. Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment. Jabs DA; Van Natta ML; Holbrook JT; Kempen JH; Meinert CL; Davis MD; Ophthalmology; 2007 Apr; 114(4):780-6. PubMed ID: 17258320 [TBL] [Abstract][Full Text] [Related]
22. Recovery of long-term natural protection against reactivation of CMV retinitis in AIDS patients responding to highly active antiretroviral therapy. Di Perri G; Vento S; Mazzi R; Bonora S; Bonora A; Trevenzoli M; Allegranzi B; Carretta G; Lanzafame M; Pizzighella S; Concia E J Infect; 1999 Nov; 39(3):193-7. PubMed ID: 10714794 [TBL] [Abstract][Full Text] [Related]
23. Paradoxical activity of CMV retinitis in patients receiving highly active antiretroviral therapy. Song MK; Schrier RD; Smith IL; Plummer DJ; Freeman WR Retina; 2002 Jun; 22(3):262-7. PubMed ID: 12055457 [TBL] [Abstract][Full Text] [Related]
24. Visual field loss in patients with cytomegalovirus retinitis. Thorne JE; Van Natta ML; Jabs DA; Duncan JL; Srivastava SK; Ophthalmology; 2011 May; 118(5):895-901. PubMed ID: 21146225 [TBL] [Abstract][Full Text] [Related]
25. Cytomegalovirus retinitis in HIV-infected patients with and without highly active antiretroviral therapy. Doan S; Cochereau I; Guvenisik N; Diraison MC; Mousalatti H; Thanh HX Am J Ophthalmol; 1999 Aug; 128(2):250-1. PubMed ID: 10458193 [TBL] [Abstract][Full Text] [Related]
26. Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy. Spanish CMV-AIDS Study Group. Casado JL; Arrizabalaga J; Montes M; Martí-Belda P; Tural C; Pinilla J; Gutierrez C; Portu J; Schuurman R; Aguirrebengoa K AIDS; 1999 Aug; 13(12):1497-502. PubMed ID: 10465073 [TBL] [Abstract][Full Text] [Related]
27. Improved outcome of cytomegalovirus retinitis in AIDS patients after introduction of protease inhibitors. Casado JL; Perez-Elías MJ; Martí-Belda P; Antela A; Suarez M; Ciancas E; Frutos B; Perez MD; Guerrero A J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Oct; 19(2):130-4. PubMed ID: 9768621 [TBL] [Abstract][Full Text] [Related]
28. Seven years of HAART impact on ophthalmic management of HIV-infected patients. Kahraman G; Krepler K; Franz C; Ries E; Maar N; Wedrich A; Rieger A; Dejaco-Ruhswurm I Ocul Immunol Inflamm; 2005; 13(2-3):213-8. PubMed ID: 16019681 [TBL] [Abstract][Full Text] [Related]
29. Cystoid macular oedema and cytomegalovirus retinitis in patients with HIV disease treated with highly active antiretroviral therapy. Cassoux N; Lumbroso L; Bodaghi B; Zazoun L; Katlama C; LeHoang P Br J Ophthalmol; 1999 Jan; 83(1):47-9. PubMed ID: 10209434 [TBL] [Abstract][Full Text] [Related]
30. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Jabs DA; Van Natta ML; Thorne JE; Weinberg DV; Meredith TA; Kuppermann BD; Sepkowitz K; Li HK; Ophthalmology; 2004 Dec; 111(12):2232-9. PubMed ID: 15582079 [TBL] [Abstract][Full Text] [Related]
31. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Jabs DA; Van Natta ML; Thorne JE; Weinberg DV; Meredith TA; Kuppermann BD; Sepkowitz K; Li HK; Ophthalmology; 2004 Dec; 111(12):2224-31. PubMed ID: 15582078 [TBL] [Abstract][Full Text] [Related]
32. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Kedhar SR; Jabs DA Herpes; 2007 Dec; 14(3):66-71. PubMed ID: 18371289 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of the United States public health service guidelines for discontinuation of anticytomegalovirus therapy after immune recovery in patients with cytomegalovirus retinitis. Holbrook JT; Colvin R; van Natta ML; Thorne JE; Bardsley M; Jabs DA; Am J Ophthalmol; 2011 Oct; 152(4):628-637.e1. PubMed ID: 21742304 [TBL] [Abstract][Full Text] [Related]
34. Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Sugar EA; Jabs DA; Ahuja A; Thorne JE; Danis RP; Meinert CL; Am J Ophthalmol; 2012 Jun; 153(6):1016-24.e5. PubMed ID: 22310076 [TBL] [Abstract][Full Text] [Related]
35. Suspension of anticytomegalovirus maintenance therapy following immune recovery due to highly active antiretroviral therapy. Curi AL; Muralha A; Muralha L; Pavesio C Br J Ophthalmol; 2001 Apr; 85(4):471-3. PubMed ID: 11264139 [TBL] [Abstract][Full Text] [Related]
36. Incidence of cytomegalovirus (CMV) retinitis in second eyes of patients with the acquired immune deficiency syndrome and unilateral CMV retinitis. Kempen JH; Jabs DA; Wilson LA; Dunn JP; West SK Am J Ophthalmol; 2005 Jun; 139(6):1028-34. PubMed ID: 15953432 [TBL] [Abstract][Full Text] [Related]
37. Effect of combination antiretroviral therapy on cytomegalovirus retinitis. Banker AS; Patel A Indian J Ophthalmol; 2002 Mar; 50(1):29-33. PubMed ID: 12090084 [TBL] [Abstract][Full Text] [Related]
38. Effects of protease inhibitors on the course of CMV retinitis in relation to CD4+ lymphocyte responses in HIV+ patients. van den Horn GJ; Meenken C; Danner SA; Reiss P; de Smet MD Br J Ophthalmol; 1998 Sep; 82(9):988-90. PubMed ID: 9893585 [TBL] [Abstract][Full Text] [Related]
39. Cytomegalovirus (CMV)-specific CD4+ T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy. Jacobson MA; Schrier R; McCune JM; Torriani FJ; Holland GN; O'Donnell JJ; Freeman WR; Bredt BM J Infect Dis; 2001 May; 183(9):1399-404. PubMed ID: 11294673 [TBL] [Abstract][Full Text] [Related]
40. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Jacobson MA; Zegans M; Pavan PR; O'Donnell JJ; Sattler F; Rao N; Owens S; Pollard R Lancet; 1997 May; 349(9063):1443-5. PubMed ID: 9164318 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]